Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues (Q34090957)

30 July 2017

title

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues (English)

1 reference

30 July 2017

Sebti SM

1

1 reference

30 July 2017

Hamilton AD

series ordinal

2

1 reference

30 July 2017

publication date

1 December 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

language of work or name

English

0 references

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

2767-2782

1 reference

publication type of scholarly work

30 July 2017

review article

1 reference

Protein prenylation: molecular mechanisms and functional consequences

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Rho family proteins and Ras transformation: the RHOad less traveled gets congested

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Inhibition of ras prenylation: A novel approach to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Inhibition of Ras and Related G-Proteins As a Therapeutic Strategy for Blocking Malignant Glioma Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

A role for Rho in Ras transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.12.2767

10.1517/13543784.9.12.2767

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference